Brief: Hansa Biopharma Announces Positive Reimbursement Decision For Idefirix In Italy
08/12/2022 07:48
Dec 8 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HANSA BIOPHARMA ANNOUNCES POSITIVE REIMBURSEMENT DECISION
IN
ITALY FOR IDEFIRIX ® (IMLIFIDASE) AS DESENSITIZATION TREATMENT
FOR HIGHLY SENSITIZED PATIENTS IN KIDNEY TRANSPLANTATION
Source text for Eikon: ID:nWkrWvMmF
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS